| |
Public Act 097-0091 Public Act 0091 97TH GENERAL ASSEMBLY |
Public Act 097-0091 | HB1191 Enrolled | LRB097 06572 RPM 46657 b |
|
| AN ACT concerning insurance.
| Be it enacted by the People of the State of Illinois, | represented in the General Assembly:
| Section 5. The Illinois Insurance Code is amended by | changing Sections 356z.16 and 364.01 as follows: | (215 ILCS 5/356z.16) | Sec. 356z.16. Applicability of mandated benefits to | supplemental policies. Unless specified otherwise, the | following Sections of the Illinois Insurance Code do not apply | to short-term travel, disability income, long-term care, | accident only, or limited or specified disease policies: 356b, | 356c, 356d, 356g, 356k, 356m, 356n, 356p, 356q, 356r, 356t, | 356u, 356w, 356x, 356z.1, 356z.2, 356z.4, 356z.5, 356z.6, | 356z.8, 356z.12, 364.01, 367.2-5, and 367e.
| (Source: P.A. 96-180, eff. 1-1-10; 96-1000, eff. 7-2-10; | 96-1034, eff. 1-1-11.) | (215 ILCS 5/364.01) | Sec. 364.01. Qualified clinical cancer trials. | (a) No individual or group policy of accident and health | insurance issued or renewed in this State may be cancelled or | non-renewed for any individual based on that individual's | participation in a qualified clinical cancer trial. |
| (b) Qualified clinical cancer trials must meet the | following criteria: | (1) the effectiveness of the treatment has not been | determined relative to established therapies; | (2) the trial is under clinical investigation as part | of an approved cancer research trial in Phase II, Phase | III, or Phase IV of investigation; | (3) the trial is: | (A) approved by the Food and Drug Administration; | or | (B) approved and funded by the National Institutes | of Health, the Centers for Disease Control and | Prevention, the Agency for Healthcare Research and | Quality, the United States Department of Defense, the | United States Department of Veterans Affairs, or the | United States Department of Energy in the form of an | investigational new drug application, or a cooperative | group or center of any entity described in this | subdivision (B); and
| (4) the patient's primary care physician, if any, is | involved in the coordination of care.
| (c) No group policy of accident and health insurance shall | exclude coverage for any routine patient care administered to | an insured who is a qualified individual participating in a | qualified clinical cancer trial, if the policy covers that same | routine patient care of insureds not enrolled in a qualified |
| clinical cancer trial. | (d) The coverage that may not be excluded under subsection | (c) of this Section is subject to all terms, conditions, | restrictions, exclusions, and limitations that apply to the | same routine patient care received by an insured not enrolled | in a qualified clinical cancer trial, including the application | of any authorization requirement, utilization review, or | medical management practices. The insured or enrollee shall | incur no greater out-of-pocket liability than had the insured | or enrollee not enrolled in a qualified clinical cancer trial. | (e) If the group policy of accident and health insurance | uses a preferred provider program and a preferred provider | provides routine patient care in connection with a qualified | clinical cancer trial, then the insurer may require the insured | to use the preferred provider if the preferred provider agrees | to provide to the insured that routine patient care. | (f) A qualified clinical cancer trial may not pay or refuse | to pay for routine patient care of an individual participating | in the trial, based in whole or in part on the person's having | or not having coverage for routine patient care under a group | policy of accident and health insurance. | (g) Nothing in this Section shall be construed to limit an | insurer's coverage with respect to clinical trials. | (h) Nothing in this Section shall require coverage for | out-of-network services where the underlying health benefit | plan does not provide coverage for out-of-network services. |
| (i) As used in this Section, "routine patient care" means | all health care services provided in the qualified clinical | cancer trial that are otherwise generally covered under the | policy if those items or services were not provided in | connection with a qualified clinical cancer trial consistent | with the standard of care for the treatment of cancer, | including the type and frequency of any diagnostic modality, | that a provider typically provides to a cancer patient who is | not enrolled in a qualified clinical cancer trial. "Routine | patient care" does not include, and a group policy of accident | and health insurance may exclude, coverage for: | (1) a health care service, item, or drug that is the | subject of the cancer clinical trial; | (2) a health care service, item, or drug provided | solely to satisfy data collection and analysis needs for | the qualified clinical cancer trial that is not used in the | direct clinical management of the patient; | (3) an investigational drug or device that has not been | approved for market by the United States Food and Drug | Administration; | (4) transportation, lodging, food, or other expenses | for the patient or a family member or companion of the | patient that are associated with the travel to or from a | facility providing the qualified clinical cancer trial, | unless the policy covers these expenses for a cancer | patient who is not enrolled in a qualified clinical cancer |
| trial; | (5) a health care service, item, or drug customarily | provided by the qualified clinical cancer trial sponsors | free of charge for any patient; | (6) a health care service or item, which except for the | fact that it is being provided in a qualified clinical | cancer trial, is otherwise specifically excluded from | coverage under the insured's policy, including: | (A) costs of extra treatments, services, | procedures, tests, or drugs that would not be performed | or administered except for the fact that the insured is | participating in the cancer clinical trial; and | (B) costs of nonhealth care services that the | patient is required to receive as a result of | participation in the approved cancer clinical trial; | (7) costs for services, items, or drugs that are | eligible for reimbursement from a source other than a | patient's contract or policy providing for third-party | payment or prepayment of health or medical expenses, | including the sponsor of the approved cancer clinical | trial; or | (8) costs associated with approved cancer clinical | trials designed exclusively to test toxicity or disease | pathophysiology, unless the policy covers these expenses | for a cancer patient who is not enrolled in a qualified | clinical cancer trial; or |
| (9) a health care service or item that is eligible for | reimbursement by a source other than the insured's policy, | including the sponsor of the qualified clinical cancer | trial. | The definitions of the terms "health care services", | "Non-Preferred Provider", "Preferred Provider", and "Preferred | Provider Program", stated in 50 IL Adm. Code Part 2051 | Preferred Provider Programs apply to these terms in this | Section. | (j) The external review procedures established under the | Health Carrier External Review Act shall apply to the | provisions under this Section. | (Source: P.A. 93-1000, eff. 1-1-05.)
| Section 99. Effective date. This Act takes effect January | 1, 2012.
|
Effective Date: 1/1/2012
|
|
|